Immunotherapy +/- EGFR Inhibitor In Advanced/Metastatic cSCC: Tackling Primary And Secondary Resistance

NCT03666325 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

43

Enrollment

OTHER

Sponsor class

Conditions

Skin Neoplasm

Interventions

DRUG: Pembrolizumab
DRUG: Cetuximab

Sponsor

Fondazione IRCCS Istituto Nazionale dei Tumori, Milano

Collaborators

[object Object]